Purpose of the study
====================

To evaluate long-term outcomes in pts maintaining a NVP-based regimen

Methods
=======

Retrospective cohort study. Pts received a NVP regimen for at least 5 years and continued up to present. Demographic, clinical, and analytical variables were recorded. A sample size of 506 pts was randomly selected from participating cohorts

Summary of results
==================

Median follow up 8.9 (5.7-11.3) years (506 pts followed ≥6 years and 270 ≥ 9 years). At baseline: 74% men, 47 years old, 36% drug users, 40% AIDS, 40% HCV+, 14% alcohol. 45% detectable VL, CD4 395/uL, 19% CD4 \< 200/uL, 27% ALT Grade 1-2, 36% AST grade 1-2. 30% ART naïve. 84% received NVP+2 nucleosides (NRTI) during the study period, 17% PI.

Most frequent current combinations were NVP+TDF/FTC in 31%, +ABC/3TC in 24% and +ZDV/3TC in 22%. 97% reached undetectable VL. In pts receiving 2 NRTI+NVP (n=423), regardless of being HCV+ or -, a significant increase was observed in general health status markers: hemoglobin, platelets and albumin (all p\<0.001), and +218 and +322 CD4 cells increase after 6 and 9 years (p\<0.001). Triglyceride levels decreased 19% and total cholesterol 4% in pretreated pts vs 9% and 12% increase in naive pts. After 6 years, the proportion of pts with lipid levels above (below in HDL) the NCEP thresholds for recommending lipid lowering therapy was 50% for TC, 43% TG, 34% LDL and 14% HDL.

Regarding liver outcomes in the 506 pts, a significant decrease in ALT and AST levels were found in naive (p=0.02, p\<0.001) and HCV+ pts (p=0.065, p\<0.001), while a strong decrease in alkaline phosphatase (AP) levels (up to -44%) was observed in naive and pretreated pts as well as in HCV+ or --- (all p\<0.001), regardless of TDF use. GGT levels increased by 78% regardless of the patient status (p\<0.001).

This favourable changes in liver function tests occurred despite 53% of 89 pts in whom biopsy or fibroscan was performed after a median of 7.1 years of NVP therapy, fibrosis (≥ F2 and/or 7≥kPa) was detected. In addition, as a consequence of transaminase and platelet changes, Fib-4 index significantly decreased in ARV naive HIV/HCV pts at 9 years (p=0.01)

Conclusions
===========

Patients receiving a long-term NVP-including regimen, show a progressive improvement in general health status and CD4 response, an acceptable lipid profile and favourable changes in liver function tests, even in those with HCV+. The marked decrease in AP levels shown in this large cohort of NVP-treated pts merits further study.
